Has Meghan Trainor confirmed using Ozempic or any GLP-1 medication?

No. As of May 2025, Trainor has not publicly confirmed using any GLP-1 receptor agonist. She has attributed her weight loss to dietary and lifestyle changes. Any claims otherwise are speculation.

Are nausea and fatigue proof someone is on a GLP-1 drug?

No. Nausea and fatigue are common during any period of significant caloric deficit. They occur with crash diets, intermittent fasting, intense exercise programs, and many medications beyond GLP-1 agonists. These symptoms are consistent with GLP-1 use but not diagnostic of it.

How long do GLP-1 side effects typically last?

Gastrointestinal side effects (nausea, vomiting, diarrhea) are most pronounced during dose escalation and typically improve within 4 to 12 weeks at a stable dose. Some patients experience persistent low-grade nausea throughout treatment. Fatigue tends to correlate with the magnitude of caloric deficit rather than treatment duration.

What percentage of people quit GLP-1 medications due to side effects?

In the STEP 1 trial, 7.0% of semaglutide-treated patients discontinued due to gastrointestinal adverse events. Real-world discontinuation rates appear higher, with some analyses suggesting 30-50% of patients stop within 12 months, though not all discontinuations are side-effect-driven.

Side Effects Meghan Trainor Publicly Discussed (and What They Match in the Clinical Literature)

By HealthRX.com Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

Clinical image for Side Effects Meghan Trainor Publicly Discussed (and What They Match in the Clinical Literature) Image: HealthRX.com clinical image

The Public Record: What Meghan Trainor Has Actually Said

Meghan Trainor's weight loss became a topic of widespread public discussion beginning in late 2023. In interviews with outlets including TODAY and People magazine, Trainor attributed her physical transformation to dietary changes, increased exercise, and working with a nutritionist. She has repeatedly emphasized a lifestyle-based approach to her weight management.

To be clear: Trainor has not publicly confirmed using semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro/Zepbound), or any other GLP-1 receptor agonist. Public speculation exists, but speculation is not evidence. The HealthRX.com Medical Team treats this distinction as non-negotiable.

What Trainor has discussed publicly are specific physical experiences during her weight-loss period. In podcast appearances and social media, she has referenced bouts of nausea, reduced appetite that she described as dramatic, and periods of low energy. These are the symptoms we examine below, purely in the context of what the clinical literature says about GLP-1-class medications.

Nausea: The Most Common GLP-1 Adverse Event

Trainor mentioned experiencing significant nausea during her weight-loss period in a 2024 podcast appearance. Whether or not this was medication-related is unknown. What is known is the clinical profile.

Nausea is the single most frequently reported adverse event across all approved GLP-1 receptor agonists. In the STEP 1 trial (semaglutide 2.4 mg weekly for weight management), 44.2% of participants in the treatment arm reported nausea, compared to 17.4% in the placebo group. The SURMOUNT-1 trial for tirzepatide showed nausea rates of 24.6% to 33.3% depending on dose tier.

The mechanism is well-characterized. GLP-1 receptor agonists slow gastric emptying through vagal afferent signaling and direct action on smooth muscle in the gastric fundus. This delayed emptying, combined with central GLP-1 receptor activation in the area postrema (the brainstem's "vomiting center"), produces the nausea that most patients experience during dose escalation.

Per the FDA prescribing information for Wegovy, nausea is typically most pronounced during the first 4 to 8 weeks and during each dose-escalation step. Most patients report meaningful improvement by week 12 at maintenance dose.

Appetite Suppression: Therapeutic Effect or Side Effect?

Trainor described her appetite decrease as surprising in its intensity. This maps directly to the primary mechanism of GLP-1 receptor agonists, though appetite reduction also occurs with caloric restriction, increased physical activity, and psychological shifts around food.

GLP-1 receptor agonists reduce appetite through dual pathways. Peripherally, delayed gastric emptying creates prolonged post-meal satiety signals. Centrally, GLP-1 receptors in the hypothalamic arcuate nucleus and the nucleus tractus solitarius modulate hunger and reward signaling. A 2023 study in Nature Medicine using fMRI demonstrated that semaglutide significantly reduced neural responses to food cues in reward-processing brain regions.

The STEP 3 trial reported that participants on semaglutide 2.4 mg experienced a mean reduction in caloric intake of approximately 35% compared to baseline. This is not a subtle effect. Patients frequently describe it as a fundamental shift in how they experience hunger, which aligns with Trainor's public characterization.

The HealthRX.com Medical Team take: Appetite suppression this pronounced can occur with intensive behavioral interventions alone, particularly when combined with high-protein dietary protocols. It is not diagnostic of GLP-1 use. The overlap is notable but insufficient to draw conclusions.

Fatigue and Low Energy

In social media posts during 2024, Trainor referenced periods of feeling "wiped out" during her transformation. Fatigue appears in GLP-1 clinical trial data, though at lower rates than gastrointestinal symptoms.

In the STEP 1 trial, fatigue was reported by 11.0% of semaglutide-treated participants versus 4.9% on placebo. The Wegovy FDA label lists fatigue among adverse reactions occurring in ≥5% of patients.

The etiology of GLP-1-associated fatigue is multifactorial. Caloric deficit itself produces fatigue regardless of mechanism. Rapid shifts in glycemic patterns (even in non-diabetic patients) can trigger lethargy as the body adapts to lower circulating glucose. A 2022 analysis in Diabetes, Obesity and Metabolism noted that fatigue correlated more strongly with rate of weight loss than with drug dose, suggesting the caloric deficit rather than the molecule itself may be the primary driver.

This means fatigue during any rapid weight-loss period is expected, whether the mechanism is pharmacological, behavioral, or both.

What the Adverse-Event Profile Actually Looks Like

At a glance

Nausea: 44% of patients in STEP 1 (semaglutide 2.4 mg); typically resolves by week 12
Vomiting: 24.8% in STEP 1; less persistent than nausea
Diarrhea: 30% in STEP 1; usually mild-to-moderate
Constipation: 24.2% in STEP 1; dose-dependent
Appetite suppression: Therapeutic intent, reported by majority of patients
Fatigue: 11% in STEP 1; correlated with caloric deficit magnitude
Headache: 14.3% in STEP 1; typically early and transient
Injection-site reactions: 3.2% in STEP 1; mild erythema or pruritus

The gastrointestinal cluster (nausea, vomiting, diarrhea, constipation) accounts for the majority of treatment discontinuations in GLP-1 trials. In STEP 1 to 7.0% of semaglutide-treated patients discontinued due to GI adverse events versus 3.1% on placebo.

Rare but Serious Adverse Events in the FDA Label

For completeness, the clinical picture includes less common but clinically significant risks. The FDA label carries warnings for:

Pancreatitis: Acute pancreatitis has been reported. Patients should discontinue if pancreatitis is suspected.
Gallbladder disease: Cholelithiasis occurred in 1.6% of semaglutide patients versus 0.7% placebo in STEP trials. Rapid weight loss itself is a known gallstone risk factor.
Thyroid C-cell tumors: A boxed warning based on rodent data. Relevance to humans at therapeutic doses remains unestablished, but semaglutide is contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2.

Trainor has not publicly reported any of these serious adverse events. This section exists solely to provide the complete clinical picture for readers evaluating GLP-1 medications.

The Distinction Between Correlation and Causation

The HealthRX.com Medical Team take: The symptoms Trainor has discussed publicly (nausea, appetite loss, fatigue) are consistent with at least three distinct scenarios: (1) GLP-1 receptor agonist use during dose titration, (2) aggressive caloric restriction with high exercise volume, or (3) a combination of lifestyle intervention with any number of supplements or medications not publicly disclosed. The symptom overlap with GLP-1 adverse events is real but not probative. Attributing these experiences to a specific medication without Trainor's own confirmation would be irresponsible, and this page does not do so.

The value here is educational. If you are considering a GLP-1 receptor agonist and want to understand what the side-effect experience typically looks like, the clinical data above represents what peer-reviewed evidence actually shows, regardless of any individual celebrity's private medical decisions.

Frequently asked questions

›

References

Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
Wadden TA, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity (STEP 3). JAMA. 2021;325(14):1403-1413. https://pubmed.ncbi.nlm.nih.gov/34170647/
Wegovy (semaglutide) prescribing information. FDA. 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
Friedrichsen M, et al. The effect of semaglutide 2.4 mg on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab. 2022;24(7):1256-1267. https://pubmed.ncbi.nlm.nih.gov/35014153/
van der Velden WJC, et al. Central GLP-1 receptor activation modulates brain responses to food cues. Nat Med. 2023;29(6):1516-1525. https://pubmed.ncbi.nlm.nih.gov/37024754/